Conflict of interest

Y. H. received honoraria (lecture fees) from AstraZeneca, Eli Lilly Japan, Taiho Pharmaceutical, Chugai Pharmaceutical, Ono Pharmaceutical, Bristol-Myers Squibb, Kyowa Kirin, Nippon Kayaku, Takeda, Eisai, Novartis, Pfizer and MSD. M.Y. received honoraria (lecture fees) from AstraZeneca, Takeda, MSD, Chugai Pharmaceutical, Ono Pharmaceutical, and Bristol-Myers Squibb. M. K. received honoraria (lecture fees) from Chugai Pharmaceutical. The other authors declare that they have no conflicts of interest.

Ethical approval

Formal consent was not required for this study.

Informed consent

Informed consent was obtained from the participant.